Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-03-01
Based on 638 first isolates · URO · Cystitis (lower UTI) · 2025-03-02 → 2026-03-01
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 88 % (85 %–90 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (5 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
88 %
78 %
n = 46
meropenem MEM
trend · Escherichia coli reserve
82 %
89 %
n = 46
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
85 %
n = 46
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
78 %
n = 46
ciprofloxacin CIP
trend · Escherichia coli
72 %
85 %
n = 46
ceftriaxone CRO
trend · Escherichia coli
72 %
78 %
n = 46
66 %
72 %
n = 46
trimethoprim TMP
trend · Escherichia coli lower UTI only
64 %
67 %
n = 46
49 %
52 %
n = 46
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
9 %
n = 46
4 %
7 %
n = 46
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
2 %
n = 46

Most likely organisms for this profile

Escherichia coli
59 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
10 %
Proteus mirabilis
5 %
Staphylococcus aureus
4 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.